IGF-2 and IGFBP-3, on the other hand, exhibited statistically significant, positive associations with colorectal cancer risk when cases were confined to those diagnosed within a relatively short time period after enrolment (within 8 years). This evidence concerns the gene IGF2 and colorectal cancer.